February is internationally dedicated to heart health. Whether as American Heart Month in the USA or as "Red February" in other countries, the message is clear: cardiovascular diseases remain the leading cause of death worldwide.
Cardiovascular diseases include, among others:
- Coronary heart disease (including heart attack)
- Stroke
- Heart failure
- Hypertension-related heart disease
- Peripheral arterial occlusive disease

According to the World Health Organization (WHO), around 20.5 million people die worldwide each year from cardiovascular diseases - this corresponds to approximately one-third of all deaths (WHO, 2023). The situation in Germany is also clear: According to the Federal Statistical Office, cardiovascular diseases were most recently responsible for around 34% of all deaths. Coronary heart disease and heart attack are particularly common.
This topic is particularly relevant for men, as they develop cardiovascular diseases on average several years earlier than women. In Germany, men die more frequently from heart attack than women, especially in middle age. In addition, epidemiological data show that men are more likely to have classic risk factors:
- Visceral abdominal fat
- High blood pressure
- Dyslipidemia (elevated LDL, lower HDL)
- Insulin resistance
- Metabolic syndrome
At the same time, men are less likely to undergo preventive examinations and, on average, seek medical help later.
Against this background, a topic has long been controversially discussed: What role does testosterone play - and is testosterone therapy (TRT) a risk to the heart?
For years, uncertainty prevailed. Individual observational studies had suggested a possible increased cardiovascular risk under testosterone therapy. The result was warning labels, uncertainty among patients, and caution in prescribing practice. Today - in 2026 - the evidence base has clearly evolved further. And that is exactly what makes Red February particularly relevant this year.
Testosterone & Heart 2026 - Why the assessment has fundamentally changed
For many years, testosterone therapy was cardiovascularly controversial. The trigger was several observational studies between 2013 and 2014, which suggested a possible increased risk of heart attack and stroke in men under testosterone therapy. The analyses by Vigen et al. (2013) and Finkle et al. (2014), which had analyzed retrospective insurance and registry data, were particularly frequently cited.
These studies had methodological weaknesses - including:
- No randomized assignment
- Incomplete adjustment for relevant risk factors
- Heterogeneous patient groups
- Partial statistical inconsistencies
Nevertheless, they caused considerable public and regulatory attention.
What happened in 2015?
In March 2015, the U.S. Food and Drug Administration (FDA) - the American drug agency - responded with an official safety notice. The FDA required:
- An adjustment of the product information of testosterone preparations
- A warning about a possible increased risk of heart attack and stroke
- The restriction of the indication to clearly diagnosed hypogonadism
This notice led to uncertainty internationally - among both doctors and patients. In many countries, testosterone was prescribed significantly more cautiously, and public perception shifted: testosterone was increasingly regarded as potentially "harmful to the heart".
Why this assessment is being re-evaluated today
The crucial point: The warnings at the time were not based on randomized, controlled long-term studies, but on observational data. However, randomized controlled studies (RCTs) are considered the gold standard when it comes to causal statements about the safety of a medication. Exactly this data was not sufficiently available in 2015.
The turning point: The TRAVERSE study
This changed with the TRAVERSE study, published in 2023 in the New England Journal of Medicine (N Engl J Med 2023; 389: 1183-1195).
Study design
- Over 5,200 men
- Age 45-80 years
- Symptomatic hypogonadism
- Existing or elevated cardiovascular risk
- Randomized: Testosterone gel vs. placebo
- Median observation period: 22 months
The central question was whether medically supervised testosterone therapy increased the risk of heart attack, stroke, or cardiovascular death.
Result
The study showed: No significantly increased risk of major cardiovascular events under testosterone therapy compared to placebo. The primary safety endpoint was met. TRT was not cardiovascularly inferior in this high-risk population. Even in men with elevated heart risk, there was thus no additional risk effect from a properly supervised therapy.
2026: The new position paper

In January 2026, an up-to-date position paper was published summarizing the TRAVERSE data, new meta-analyses of randomized studies, real-world data, and pharmacovigilance registry data.
The conclusion is more clearly formulated than ever before:
With correctly diagnosed hypogonadism and adequate monitoring, testosterone therapy is to be classified as safe from a cardiovascular perspective.
The potential benefits can outweigh the risks.
This re-evaluation also supports the recent adjustments to the FDA labeling, which relativize the blanket perception of risk.
The prerequisite for any responsible therapy is a clear diagnosis. This includes a comprehensive test that considers not only the total testosterone level, but also relevant accompanying parameters, such as the Premium Testosterone Test.
Why this is relevant for men

Low testosterone is associated with metabolic risk factors even on its own:
- Elevated visceral fat
- Insulin resistance
- Dyslipidemia
- Inflammatory markers
- Increased overall mortality
Untreated hypogonadism can thus itself be part of a cardiometabolic risk profile. The discussion has therefore shifted. Previously, the question was: "Is testosterone dangerous for the heart?" Today, it is: "What does it mean for the heart and metabolism if a relevant hormone deficiency remains untreated?"
Anyone who wants to know how their own hormone status is should not speculate, but measure. Structured laboratory diagnostics create clarity - especially when metabolic risk factors are already present. Here is the link to the Premium Testosterone Test.
And what does that have to do with Adon Health?
The crucial message from the current evidence is not: Testosterone is harmless. Rather: Testosterone is safe - if it is used medically correctly.
This means:
- Clear indication
- Objective laboratory diagnostics
- Risk stratification
- Regular follow-up checks
- Monitoring of hematocrit, lipids, blood pressure, and PSA
Exactly this structured approach is the basis of our medical processes. Red February stands for heart health, and modern men's health means not thinking about hormonal and cardiometabolic connections separately. The evidence today is more robust than ever before and allows for a differentiated, objective assessment.
